ArticleAnnals of internal medicine2011
Enhancing prescription drug innovation and adoption.
Article in Annals of internal medicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- The reimbursement process in three national healthcare systems: variation in time to reimbursement of pembrolizumab for metastatic non-small cell lung cancer.Journal of pharmaceutical policy and practice · 2023Review
- Adverse Events Associated With Radium-223 in Metastatic Prostate Cancer: Disproportionality Analysis of FDA Data Reflecting Worldwide Utilization.Clinical genitourinary cancer · 2020Article
- Patterns and predictors of physician adoption of new cardiovascular drugs.Healthcare (Amsterdam, Netherlands) · 2018Article
- Regional variation in use of a new class of antidiabetic medication among medicare beneficiaries: the case of incretin mimetics.The Annals of pharmacotherapy · 2015Article
- Academic centers play a vital role in the study of drug safety and effectiveness.Clinical therapeutics · 2013Article
- Designing concept maps for a precise and objective description of pharmaceutical innovations.BMC medical informatics and decision making · 2013Article
- National trends in oral anticoagulant use in the United States, 2007 to 2011.Circulation. Cardiovascular quality and outcomes · 2012Article
- Is treatment heterogeneity an Achilles' heel for comparative effectiveness research?Pharmacotherapy · 2012Article
- Modeling chemical interaction profiles: II. Molecular docking, spectral data-activity relationship, and structure-activity relationship models for potent and weak inhibitors of cytochrome P450 CYP3A4 isozyme.Molecules (Basel, Switzerland) · 2012Article
- Adoption of new drugs by physicians: a survival analysis.BMC health services research · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The adoption and use of a new drug would ideally be guided by its innovation and cost-effectiveness. However, information about the relative efficacy and safety of a drug is typically incomplete even well after market entry, and various other forces create a marketplace in which most new drugs are little better than their older counterparts. Five proposed mechanisms are considered for promoting innovation and reducing the use of therapies ultimately found to offer poor value or have unacceptable risks. These changes range from increasing the evidence required for U.S. Food and Drug Administration approval to modifying the structure of drug reimbursement. Despite the challenges of policy implementation, the United States has a long history of successfully improving the societal value and safe use of prescription medicines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.